Literature DB >> 21148451

De novo sustained refractory status epilepticus and encephalopathy: a retrospective case series.

Joanna S Fong1, Stephen Hantus, Ebru Erbayat Altay, Ingrid Tuxhorn.   

Abstract

Refractory status epilepticus is a devastating persistent seizure state with a poor prognosis that requires emergency medical management. Recent studies have reported de novo, idiopathic refractory status epilepticus of unclear etiology in healthy young patients followed by severe neurologic sequelae. We present a series of 7 cases of de novo sustained refractory status epilepticus. We found that all patients were young and previously healthy and that, prior to the onset of refractory status epilepticus, all had prodromal viral-like symptoms. The onset of refractory status epilepticus was explosive and intractable, resulting in prolonged hospital stay and dependence on multiple antiepileptic medications. Clinical outcome was poor in all 7 patients. The laboratory findings suggest a possible immune activation that can have persisted in the nervous system after a nonspecific infection. We report on these patients so as to raise awareness of this unique entity to facilitate early diagnosis and treatment.

Entities:  

Mesh:

Year:  2010        PMID: 21148451     DOI: 10.1177/0883073810376442

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  2 in total

1.  Evaluation of positive and negative predictors of seizure outcomes among patients with immune-mediated epilepsy: a meta-analysis.

Authors:  Divyanshu Dubey; Zehra Farzal; Ryan Hays; L Steven Brown; Steven Vernino
Journal:  Ther Adv Neurol Disord       Date:  2016-07-04       Impact factor: 6.570

2.  Outcomes in Children Treated with Pentobarbital Infusion for Refractory and Super-Refractory Status Epilepticus.

Authors:  Jennifer Erklauer; Jeanine Graf; Mona McPherson; Anne Anderson; Angus Wilfong; Charles G Minard; Laura Loftis
Journal:  Neurocrit Care       Date:  2018-10       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.